Development of energy efficient design proposals for air conditioned mosques: Temperate humid climate case

por Atmaca, A.B., Zorer Gedik, G.
Publicado 2023

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial

por Atmaca, A, Al-Batran, S-E, Maurer, A, Neumann, A, Heinzel, T, Hentsch, B, Schwarz, S E, Hövelmann, S, Göttlicher, M, Knuth, A, Jäger, E
Publicado 2007

New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma

por Wedel, S A, Sparatore, A, Soldato, P D, Al-Batran, S-E, Atmaca, A, Juengel, E, Hudak, L, Jonas, D, Blaheta, R A
Publicado 2008

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

por Haense, N., Atmaca, A., Pauligk, C., Steinmetz, K., Marmé, F., Haag, G. M., Rieger, M., Ottmann, O. G., Ruf, P., Lindhofer, H., Al-Batran, S.-E.
Publicado 2016

The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial

por Al-Batran, S-E, Bischoff, J, von Minckwitz, G, Atmaca, A, Kleeberg, U, Meuthen, I, Morack, G, Lerbs, W, Hecker, D, Sehouli, J, Knuth, A, Jager, E
Publicado 2006

A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology

por Al-Batran, S.-E., Mueller, D.W., Rafiyan, M.-R., Kiselicki, D., Atmaca, A., Habibzada, T., Mueller, C., Brignone, C., Triebel, F., Loose, M., Schaaf, M., Sookthai, D., Eickhoff, R., Jaeger, E., Goetze, T.O.
Publicado 2023

No association of anti-osteoporosis drugs with COVID-19-related outcomes in women: a nationwide cohort study

por Atmaca, A., Demirci, I., Haymana, C., Tasci, I., Sahin, I., Cakal, E., Ata, N., Dagdelen, S., Salman, S., Emral, R., Sahin, M., Celik, O., Demir, T., Ertugrul, D., Unluturk, U., Caglayan, M., Satman, I., Sonmez, A.
Publicado 2021

A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer

por Atmaca, A, Al-Batran, S-E, Werner, D, Pauligk, C, Güner, T, Koepke, A, Bernhard, H, Wenzel, T, Banat, A-G, Brueck, P, Caca, K, Prasnikar, N, Kullmann, F, Günther Derigs, H, Koenigsmann, M, Dingeldein, G, Neuhaus, T, Jäger, E
Publicado 2013